[PDF] VI-0521 (QNEXA®) ADVISORY COMMITTEE BRIEFING ... [Advisory Committees]
| www.fda.gov/.../Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM292317.pdf - Text Version Page 1. VI-0521 (QNEXA®) ADVISORY COMMITTEE BRIEFING DOCUMENT ... VI-0521 (QNEXA®) Advisory Committee Briefing Document ... |
[PDF] VI-0521 (QNEXA™) ADVISORY COMMITTEE BRIEFING ... [Advisory Committees]
www.fda.gov/.../Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM218821.pdf - Text Version
Page 1. VIVUS, Inc. NDA 022580 VI-0521 (QNEXA®) Advisory Committee
Briefing Document VI-0521 (QNEXA ® ) Briefing Document ...
July 15, 2010: Endocrinologic and Metabolic Drugs Advisory ... [Advisory Committees]
| www.fda.gov/AdvisoryCommittees/Calendar/ucm214795.htm - 10k - 2010-06-08 - cached ... the committee will discuss the safety and efficacy of new drug application (NDA) 22–580, proposed tradename, QNEXA (phentermine/topiramate ... |
February 22, 2012: Endocrinologic and Metabolic Drugs ... [Advisory Committees]
www.fda.gov/AdvisoryCommittees/Calendar/ucm285136.htm - 11k - 2011-12-27 - cached
... the committee will discuss the safety and efficacy of new drug application
(NDA) 22-580, proposed trade name QNEXA (phentermine/topiramate ...
Slides for the July 15, 2010 Meeting of the Endocrinologic and ... [Advisory Committees]
| www.fda.gov/.../Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm227049.htm - 9k - 2010-09-23 - cached ... FDA. FDA Core Presentations, QNEXA (phentermine/topiramate) Controlled Release Capsules, for the July 15, 2010 Meeting of the Endocrinologic ... |
Briefing Information for the July 15, 2010 Meeting of the ... [Advisory Committees]
www.fda.gov/.../Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm218819.htm - 9k - 2010-07-13 - cached
... FDA Briefing Information, (NDA) 22–580, proposed tradename, QNEXA
(phentermine/topiramate) Controlled Release Capsules, for the July 15 ...
[PDF] Global Summit on Regulatory Science Research: Modernizing ... [About FDA]
| www.fda.gov/.../CentersOffices/OC/OfficeofScientificandMedicalPrograms/NCTR/WhatWeDo/UCM319127.pdf - Text Version ... Date Drug Therapeutic target Functional adverse effect Outcome 29 Oct Qnexa Obesity Tachycardia [and embryotox] Non-approval (US) ... |
In order to show you the most relevant results, we have omitted some entries very similar to the 7 already displayed.
If you like, you can repeat the search with the omitted results included.
